BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 22989066)

  • 21. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy.
    Grytli HH; Fagerland MW; Fosså SD; Taskén KA; Håheim LL
    Prostate; 2013 Feb; 73(3):250-60. PubMed ID: 22821802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.
    Coldman AJ; Phillips N; Pickles TA
    CMAJ; 2003 Jan; 168(1):31-5. PubMed ID: 12515782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.
    Seiler D; Randazzo M; Klotz L; Grobholz R; Baumgartner M; Isbarn H; Recker F; Kwiatkowski M
    BJU Int; 2012 Jul; 110(2):195-200. PubMed ID: 22093744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients].
    Arrizabalaga Moreno M; García González JI; Diez Rodríguez JM; Esteban Artiaga R; Castro Pita M; Navarro Sebastian J; Mora Durbán M; Paniagua Andrés P
    Actas Urol Esp; 1997 Oct; 21(9):852-61. PubMed ID: 9471868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
    Dai B; Qu Y; Kong Y; Ye D; Yao X; Zhang S; Wang C; Zhang H; Yang W
    BJU Int; 2012 Dec; 110(11 Pt B):E667-72. PubMed ID: 22974446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.
    Barocas DA; Cowan JE; Smith JA; Carroll PR;
    J Urol; 2008 Oct; 180(4):1330-4; discussion 1334-5. PubMed ID: 18707731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng/mL: observation and clinical implications from Tyrol screening project.
    Pelzer AE; Tewari A; Bektic J; Berger AP; Frauscher F; Bartsch G; Horninger W
    Urology; 2005 Nov; 66(5):1029-33. PubMed ID: 16286118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
    BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006.
    Bray F; Klint A; Gislum M; Hakulinen T; Engholm G; Tryggvadóttir L; Storm HH
    Acta Oncol; 2010 Jun; 49(5):644-54. PubMed ID: 20151937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990].
    Grosclaude P; Menegoz F; Schaffer P; Macé Lesec'h J; Arveux P; Le Mab G; Soulié M; Villers A
    Prog Urol; 1997 Sep; 7(4):647-54. PubMed ID: 9410328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An incidence model of the cost of advanced prostate cancer in Spain.
    Hart WM; Nazir J; Baskin-Bey E
    J Med Econ; 2014 Feb; 17(2):125-31. PubMed ID: 24350997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population-based incidence of basal cell carcinoma in a Spanish Mediterranean area.
    Bielsa I; Soria X; Esteve M; Ferrándiz C;
    Br J Dermatol; 2009 Dec; 161(6):1341-6. PubMed ID: 19796178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes.
    Pfeiffer D; Berger J; Gross AJ
    BJU Int; 2012 Dec; 110(11):1702-7. PubMed ID: 22928703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
    van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
    BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.